OC
XENE icon

Oppenheimer & Co’s Xenon Pharmaceuticals XENE Stock Holding History

Oppenheimer & Co’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,615
Closed -$451K – 1485
2023
Q1 		$451K Buy
+12,615
New +$466K 0.01% 978
2022
Q4 		– Sell
-11,113
Closed -$401K – 1443
2022
Q3 		$401K Buy
+11,113
New +$400K 0.01% 977

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Oppenheimer & Co's XENE Position: Q2 2023 in Review

Oppenheimer & Co sold out of Xenon Pharmaceuticals (XENE) in Q2 2023, closing a stake of 12,615 shares — an estimated $451K sold.

Oppenheimer & Co first reported a position in XENE in Q3 2022 and held it in 2 quarters. The position peaked at $451K in Q1 2023. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2023.

  • Oppenheimer & Co reported no remaining Xenon Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Oppenheimer & Co sold 12,615 Xenon Pharmaceuticals shares in Q2 2023, an estimated $451K.
  • Oppenheimer & Co first reported a position in Xenon Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Oppenheimer & Co's Xenon Pharmaceuticals position peaked at $451K in Q1 2023.
  • 175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2023.

Based on Oppenheimer & Co's 13F filing for Q2 2023, filed 3 Aug 2023.